ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
37.04
+0.30 (0.82%)
After Hours: 37.20 +0.16 (0.43%)
Jul 29, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.91 - 37.20
52 week 16.64 - 49.70
Open 36.62
Vol / Avg. 1.21M/2.17M
Mkt cap 4.11B
P/E     -
Div/yield     -
EPS -1.68
Shares 113.16M
Beta 3.44
Inst. own 101%
Aug 4, 2016
Q2 2016 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 21, 2016
ACADIA Pharmaceuticals Inc at JMP Securities Life Sciences Conference - Webcast
Jun 14, 2016
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 10, 2016
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting
Jun 8, 2016
ACADIA Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference
May 11, 2016
ACADIA Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Q1 2016 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
May 5, 2016
Q1 2016 ACADIA Pharmaceuticals Inc Earnings Release
May 2, 2016
ACADIA Pharmaceuticals Inc to discuss the FDA approval of NUPLAZID - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1244050.00% -269578.70%
Operating margin -1256550.00% -269855.80%
EBITD margin - -268795.10%
Return on average assets -57.98% -60.09%
Return on average equity -61.89% -64.58%
Employees 320 -
CDP Score - -

Address

3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist (SSIA), targeting 5-HT2A receptors. The Company's Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson's disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist preferentially targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson's disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.

Officers and directors

Stephen R. Biggar M.D. Ph.D. Chairman of the Board
Age: 45
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Chief Financial Officer, Director
Age: 54
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 60
Bio & Compensation  - Reuters
Srdjan Stankovic M.D. Executive Vice President, Head - Research and Development
Age: 58
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 50
Bio & Compensation  - Reuters
James M. Daly Director
Bio & Compensation  - Reuters
Edmund P. Harrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 58
Bio & Compensation  - Reuters
Daniel B. Soland Independent Director
Age: 56
Bio & Compensation  - Reuters